We propose a new UPCI Shared Resource Facility, entitled the Cancer Biomarkers Facility (CBF), which is motivated by the current and rapidly growing demand from UPCI basic and clinical investigators for integrated and cross-disciplinary biomarker investigations. This shared resource is Cancer Center managed. Recent publications and results from UPCI researchers demonstrate that biomarker research studies, particularly approaches utilizing cutting-edge molecular analysis technological platforms, offer abundant promise for molecular diagnosis and classification of human malignancies. Studies utilizing cutting-edge analytical platforms are expected to rapidly lead to translational applications for improved detection, diagnosis, and prognosis, and for determining efficacy of cancer treatments in patients. The CBF, and its constituent technical platforms, have already provided, and will continue to provide into the next funding period of the UPCI Cancer Center Support Grant (CCSG), clinical applications of state-of-theart systems level molecular profiling that make a major impact on cancer diagnosis, assessment of prognosis, and response to treatment. Accordingly, the mission of the CBF is to provide faculty expertise and collaborative consultation including integrative bioinformatics support across the spectrum of these """"""""omics"""""""" technologies, instrumentation, and resources, and together with trained technical staff, to work with UPCI basic and clinical researchers in translational research studies focused on identifying, characterizing, and validating biomarkers for cancer risk prediction, eariy detection and screening, diagnosis, molecular classification/differential diagnosis, prognosis/prediction of disease progression, patient selection/stratification and treatment selection, prediction of therapeutic response, treatment response monitoring/assessment, and metastasis and recurrence prediction and monitoring. The proposed integrated CBF has been established and developed over the current CCSG funding period with sustained investment by UPCI building on the existing strong foundation of established UPCI shared facilities and resident instrumentation and capabilities, together with highly relevant ongoing NCI-funded translational research studies utilizing these resources, including the Eariy Detection Research Network Biomarkers Discovery Laboratory, and the Lung Cancer, Head and Neck Cancer, and Skin Cancer SPORE grants to UPCI faculty investigators. The systems level studies toward identification and validation of novel cancer biomarkers conducted within the CBF are enabled by the following technical platforms presently established and implemented at UPCI: Mass Spectrometry, Microarray, Luminex, and lllumina. Combined with integrated bioinformatics support from the UPCI Cancer Informatics Services (CIS), the CBF provides comprehensive """"""""omics"""""""" technology and expertise in a fully integrated systems biology scientific environment to support the basic, clinical, and translational research needs of UPCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705406
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$266,864
Indirect Cost
$90,326
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6

Showing the most recent 10 out of 885 publications